- Home
- SYRE vs FLR Comparison
SYRE vs FLR Comparison
Compare SYRE & FLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SYRE | FLR |
|---|---|---|
| Founded | 2013 | 1912 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 7.0B |
| IPO Year | 2015 | 2006 |
Fundamental Metrics
Financial Performance| Metric | SYRE | FLR |
|---|---|---|
| Price | $82.77 | $49.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 9 |
| Target Price | ★ $119.93 | $61.56 |
| AVG Volume (30 Days) | 1.4M | ★ 2.1M |
| Earning Date | 11-03-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.89 |
| Revenue | N/A | ★ $15,503,000,000.00 |
| Revenue This Year | N/A | $7.54 |
| Revenue Next Year | N/A | $9.93 |
| P/E Ratio | ★ N/A | $26.29 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.01 | $39.33 |
| 52 Week High | $110.18 | $58.35 |
Technical Indicators
Market Signals| Indicator | SYRE | FLR |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 40.30 |
| Support Level | $82.86 | $47.21 |
| Resistance Level | $94.10 | $53.95 |
| Average True Range (ATR) | 4.63 | 1.72 |
| MACD | -0.13 | -0.09 |
| Stochastic Oscillator | 33.91 | 31.94 |
Price Performance
Historical ComparisonAbout SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About FLR Fluor Corporation
Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services. It serves a wide range of end markets, including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $15.5 billion in revenue in 2025.